Company Overview and News

2
The 'outliers': 23 top companies lack women in top leadership

2018-09-03 theage.com.au
There are just 14 female chief executives running the top 200 listed companies and only 24 female chief financial officers, a new snapshot of corporate Australia's shows, amid calls for the quick promotion of women in business line roles.
PILBF JBHHY JHIUF LYSCF EVN SNDFY MALRY SCPAF SOUTF SRXTY MIN CCLAY CCL GWAXY INCZY SFR CAHPF WNARF WSA PLS SRX SXMDF GMA BWP JHX JHX CCLAF JBH WHC SXL TNE SFRRF LYSDY MALRF SCP EHE ICPVF IPL

2
The 'outliers': 23 top companies lack women in top leadership

2018-09-03 smh.com.au
There are just 14 female chief executives running the top 200 listed companies and only 24 female chief financial officers, a new snapshot of corporate Australia's shows, amid calls for the quick promotion of women in business line roles.
PILBF JBHHY JHIUF LYSCF EVN SNDFY MALRY SCPAF SOUTF SRXTY MIN CCLAY CCL GWAXY INCZY SFR CAHPF WNARF WSA PLS SRX SXMDF GMA BWP JHX JHX CCLAF JBH WHC SXL TNE SFRRF LYSDY MALRF SCP EHE ICPVF IPL

 
WA listed companies reach highest value since 2011

2018-08-06 australianmining.com.au
Deloitte’s latest WA Index has shown that the value of Western Australia-based listed companies has jumped by 26.8 per cent to $193.5 billion during the 2018 financial year, the highest level since May 2011.
PLS WOPEF PILBF BWP TGN LYSCF EOHDF MALRY IGO IIDDY WPL RGRNF MIN AMSLF WOPEY AUZ EHL LYSDY RRL MALRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BWP / BWP TRUST on message board site Silicon Investor.

Banco Wiese (NYSE:BWP) Banco Wiese (NYSE:BWP) Banco Wiese (NYSE:BWP)